Product Code: RP-ID-10151782 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151782
Market Overview:
Global Nanotechnology in Drug Delivery Industry Market Research 2022-2030
"Nanotechnology in drug delivery market is expected to reach USD 200 billion by the end of 2030, projected to escalate at CAGR of ~20% over the period 2022-2030. Nanotechnology is widely used in medicine, using the new properties of materials to operate at the molecular level. The main demand in the medical field in this area is to improve treatment delivery and health care outcomes. Nanotechnology drug delivery refers to the use of nano-level healthcare materials and technologies in drug delivery to improve the efficacy of drugs.
The increasing prevalence of chronic diseases, cancers, and cardiovascular diseases has increased the demand for new drugs with targeted delivery and better efficacy than traditional drugs. This factor has created a demand for nanotechnology drug delivery systems. In addition, the continuous advancement of nanotechnology and the increasing preference for personalized medicine have also promoted the growth of the market; however, the cost of nanotechnology drug delivery and strict regulations on the approval mechanism have restricted market growth.
Main market trends:
Cardiovascular applications are expected to occupy a larger market share. Cardiovascular disease (CVD) is the world leading cause of death. According to estimates by the World Health Organization, an estimated 17.9 million people died of cardiovascular disease in 2016, accounting for 31% of all deaths worldwide. Of these deaths, 85% were due to heart attacks and strokes. In addition, some other reports also reported an increase in the prevalence and number of deaths from cardiovascular diseases, which are expected to increase in the future.
According to estimates by the American Heart Association, the annual death toll is estimated to increase to 23 or 6 million. By 2030. The increase in the number of deaths will increase the burden on people, thereby increasing the demand for new nanotechnology drug delivery technologies that are more effective than traditional medicine, so it is expected that this will drive the growth of the entire market.
North America is expected to dominate the nanotechnology drug supply market over the period 2022-2030. North American countries have a high prevalence of cardiovascular disease (CVD) and cancer.
According to data from the National Cancer Institute in the United States, in 2018, it is estimated that 1.73 million new cancer cases will be diagnosed in the United States, and more than 600,000 people will die from the disease. According to data reported by the World Health Organization in 2018, nearly 24% of Mexico's deaths in 2016 were attributed to cardiovascular disease, making it the leading cause of death in Mexico.
According to the American Heart Association, cardiovascular disease (CVD) is listed as a potential cause of death. In 2016, there were 840,678 deaths in the United States. These high prevalence rates have increased the demand for new nanotechnology drug delivery technologies.
Competitive landscape:
More and more companies invest in R&D in this field, thereby increasing R&D activities and helping the market expand at a constant rate. In recent years, cooperation between large pharmaceutical companies and technology developers has also accelerated the pace of the market. Several companies are also focusing on the development of nanomedicines for the treatment of various cancers.
Major Players
Taiwan Liposome Company
Nanobiotix
NanoCarrier Co Ltd
Tarveda Therapeutics
Aquanova AG"
Related Reports
Proof of Quality & Reliability
